PRESS RELEASE published on 10/13/2026 at 18:10, 29 days 2 hours ago Inside Information / Other news releases Medincell secures €13.8 million non-dilutive financing, totaling €41.8 million. Debt maturity extended through 2031. No equity instruments used for financing Debt Maturity Non-dilutive Financing Bpifrance Medincell European Commercial Banks
PRESS RELEASE published on 10/13/2026 at 18:10, 29 days 2 hours ago Informations privilégiées / Autres communiqués Medincell obtient un financement non dilutif de 13,8 M€, portant le total à 41,8 M€ depuis juillet 2026. Aucune dilution pour les actionnaires. Détails sur la structure financière et les traitements innovants Biopharmaceutique Structure Financière Financement Non Dilutif Medincell Traitements Innovants
BRIEF published on 10/09/2026 at 15:03, 1 month 2 days ago Medincell reprend sa cotation sur Euronext Paris Euronext Paris Approbation De La FDA Medincell Reprise Des Échanges Technologie BEPO
BRIEF published on 10/09/2026 at 15:03, 1 month 2 days ago Medincell Resumes Trading on Euronext Paris Euronext Paris FDA Approval Trading Resumption Medincell BEPO Technology
BRIEF published on 10/09/2026 at 15:03, 1 month 2 days ago Reprise de la cotation des actions Medincell sur Euronext Paris FDA Euronext Medincell Teva Olanzapine LAI
BRIEF published on 10/09/2026 at 15:03, 1 month 2 days ago Medincell shares resume trading on Euronext Paris FDA Euronext Medincell Teva Olanzapine LAI
PRESS RELEASE published on 10/09/2026 at 14:58, 1 month 2 days ago Inside Information / Other news releases Medincell resumes trading on Euronext Paris after temporary suspension. The company specializes in long-acting injectable treatments using innovative technologies Innovation Euronext Paris Trading Medincell Long-acting Injectable Treatments
PRESS RELEASE published on 10/09/2026 at 14:58, 1 month 2 days ago Informations privilégiées / Autres communiqués Reprise de cotation des actions Medincell sur Euronext Paris le 9 octobre 2026 à 14h45. Medincell, société biopharmaceutique innovante, développe des traitements injectables à action prolongée dans divers domaines thérapeutiques Euronext Actions Biopharmaceutique Cotation Medincell
BRIEF published on 10/09/2026 at 14:01, 1 month 2 days ago Medincell receives FDA approval for WELTRUZA™ FDA Schizophrenia Medincell Olanzapine WELTRUZA™
BRIEF published on 10/09/2026 at 14:01, 1 month 2 days ago Medincell obtient l'approbation de la FDA pour WELTRUZA™ FDA Schizophrénie Medincell Olanzapine WELTRUZA™
Published on 11/11/2026 at 19:31, 44 minutes ago Lion Copper Corp. Completes S-K 1300 Technical Report Summary for Bear Copper Deposit
Published on 11/11/2026 at 16:30, 3 hours 45 minutes ago ShelfieTech Announces Expansion Agreement for Its Next-Generation AI Retail Intelligence Platform
Published on 11/11/2026 at 14:25, 5 hours 50 minutes ago Route1 Announces 2026 Annual Meeting Results
Published on 11/11/2026 at 14:00, 6 hours 15 minutes ago PPX Mining Reports Callanquitas Operating Results for the First Nine Months of 2026
Published on 11/11/2026 at 14:00, 6 hours 15 minutes ago NuRAN Wireless Board Approves Growth Strategy to Scale Recurring Revenue from 5,000+ Contracted Towers
Published on 11/11/2026 at 19:29, 46 minutes ago EQS-Adhoc: Allianz SE: Allianz delivers record nine-month result of 14.1 billion euros and raises 2026 outlook
Published on 11/11/2026 at 18:41, 1 hour 33 minutes ago AUSTRIACARD HOLDINGS AG: 9M 2026 Financial Results
Published on 11/10/2026 at 18:00, 1 day 2 hours ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 1 day 2 hours ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 1 day 2 hours ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 1 day 2 hours ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
